Nine for 2021: Addressing the pandemic legacyIn this second ‘Nine for 2021‘ article, IQVIA’s Sarah Rickwood looks at four issues which will directly impact Share XNine for 2021: Addressing the pandemic legacyhttps://pharmaphorum.com/views-analysis-sales-marketing/nine-for-2021-pandemic-legacy/
US, EU reviews start for Novartis’ Ocrevus rival ofatumumabNovartis’ cancer therapy ofatumumab has moved closer to its second life as a treatment for multiple sclerosis, with Share XUS, EU reviews start for Novartis’ Ocrevus rival ofatumumabhttps://pharmaphorum.com/news/us-eu-reviews-start-for-novartis-ocrevus-rival-ofatumumab/
Finding the big picture for Alzheimer’sThe $4m Oskar Fischer Prize hopes to catalyse a breakthrough in Alzheimer’s research by encouraging a ‘big picture’ Share XFinding the big picture for Alzheimer’shttps://pharmaphorum.com/r-d/views-analysis-r-d/finding-the-big-picture-for-alzheimers/
A bright future for CNS and Alzheimer’s?Swiss biotech Asceneuron is developing what could be the first treatment for progressive supranuclear palsy (PSP), a rare Share XA bright future for CNS and Alzheimer’s?https://pharmaphorum.com/r-d/views-analysis-r-d/a-bright-future-for-cns-and-alzheimers/
Regeneron and Alnylam announce $1bn collaborationRegeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and Share XRegeneron and Alnylam announce $1bn collaborationhttps://pharmaphorum.com/news/regeneron-and-alnylam-announce-1bn-collaboration/
Pfizer’s CNS exit takes the form of a biotech spinoutPfizer’s plans to duck out of central nervous system R&D have come to fruition, with the creation of Share XPfizer’s CNS exit takes the form of a biotech spinouthttps://pharmaphorum.com/news/pfizers-cns-exit-takes-the-form-of-a-biotech-spinout/
Tysabri failure in stroke a setback for BiogenBiogen’s hopes that one of its established multiple sclerosis drugs might also help stroke sufferers have been dashed. Share XTysabri failure in stroke a setback for Biogenhttps://pharmaphorum.com/news/tysabri-failure-stroke-setback-biogen/
Looking back, looking forward – Janssen’s 60 years on the psychiatry horizonImproving targeted treatments and partnering on initiatives to reduce stigma and support mental health patients. Share XLooking back, looking forward – Janssen’s 60 years on the psychiatry horizonhttps://pharmaphorum.com/views-and-analysis/janssen-mental-health-psychiatry/
Ex-Novartis chief Epstein joins Remedy PharmaceuticalsDavid Epstein, who left his job as head of Novartis’ pharma division in May, has joined Remedy Pharmaceuticals Share XEx-Novartis chief Epstein joins Remedy Pharmaceuticalshttps://pharmaphorum.com/news/ex-novartis-chief-epstein-joins-remedy-pharmaceuticals/